Filing Flows

Filing Flows › Thermo Fisher Scientific (TMO) › Q3 2026

Thermo Fisher Scientific (TMO) Q3 2026 earnings results (third quarter 2026)

10-Q filed Oct 30, 2026

Thermo Fisher Scientific (TMO) reported revenue of $12.1B for the third quarter 2026 (Q3 2026), +9% from a year earlier and +1% from the quarter before. Operating margin was 18.6%, net earnings $1.7B (14.2% of revenue).

Revenue$12.1B
Year over year+9%
Quarter over quarter+1%
Operating margin18.6%
Net earnings$1.7B

Thermo Fisher Scientific, Q3 2026: revenue $12.1B (+9% year over year), operating margin 18.6%, net earnings $1.7B, operating cash flow $2.5B. The chart follows the revenue to costs, profit and cash.

Q3 2026AmountQ/QY/Y
Revenue$12.1B+1%+9%
Operating profit$2.3B+8%+17%
Net earnings$1.7B-0.8%+7%
Operating cash flow$2.5B+20%+14%
Free cash flow$2.1B+26%+15%

What changed

Revenue was $12.1B in Q3 2026, up 9% year over year and up 1% from the previous quarter. Laboratory Products and Biopharma Services was the largest line at 56% of revenue. Laboratory Products and Biopharma Services added $0.89B year over year (up 15%), 88% of the total change. Specialty Diagnostics declined 6%.

Operating profit was $2.3B, a 18.6% margin (up 1.2 points year over year). Of the extra revenue versus Q3 2025, 32% reached operating profit, above the 17% margin then. Total costs grew 8% against revenue growth of 9%. Net earnings were $1.7B, up 6% year over year. The effective tax rate was 16.9%.

Operating cash flow was $2.5B (up 14% year over year), 148% of net earnings. Non-cash charges added back $0.82B of depreciation and amortization and $0.10B of share-based compensation. Capital expenditures of $0.44B left free cash flow of $2.1B.

Questions

What was Thermo Fisher Scientific's revenue in the third quarter 2026?

Thermo Fisher Scientific (TMO) reported revenue of $12.1B for the third quarter 2026 (Q3 2026), +9% from a year earlier and +1% from the quarter before.

Was Thermo Fisher Scientific profitable in the third quarter 2026?

Operating profit was $2.3B (18.6% of revenue) and net earnings $1.7B.

Open the interactive Sankey →

Source: Thermo Fisher Scientific 10-Q on SEC EDGAR.